Jiménez-Jorge Silvia, Pozo Francisco, Larrauri Amparo
National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no.5, 28029 Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
Institute of Health Carlos III, National Centre for Microbiology, National Influenza Centre, 28220 Majadahonda, Madrid, Spain.
Vaccine. 2015 Jun 26;33(29):3276-80. doi: 10.1016/j.vaccine.2015.03.051. Epub 2015 Apr 11.
The agreement between interim and final influenza vaccine effectiveness (VE) estimates would support the use of interim assessments as a proxy for final VE results to guide health authorities in influenza prevention. We aimed to compare interim/final VE estimates in Spain.
We used a test-negative case-control study (cycEVA) for 2010/11-2013/14 seasons. Sensitivity analyses were carried out by type/subtype of influenza virus and by target groups for vaccination.
In general, interim estimates were higher compared to end-season estimates. Interim and final VE differences were higher for the target groups compared to all population. Subtype-specific interim/final VE estimates showed greater concordance (3-13%) than for any virus (7-24%).
In Spain, interim influenza VE estimates over 2010-2014 were a good proxy of the final protection of the vaccine. Interim and final estimates showed greater concordance for all population and if performed subtype-specific.
流感疫苗效力（VE）的中期估计值与最终估计值之间的一致性，将支持把中期评估作为最终VE结果的替代指标，以指导卫生当局开展流感预防工作。我们旨在比较西班牙的中期/最终VE估计值。
我们针对2010/11 - 2013/14季节开展了一项检测呈阴性的病例对照研究（cycEVA）。按流感病毒的类型/亚型以及疫苗接种目标群体进行了敏感性分析。
总体而言，与季末估计值相比，中期估计值更高。与所有人群相比，目标群体的中期和最终VE差异更大。特定亚型的中期/最终VE估计值显示出比任何病毒（7 - 24%）更高的一致性（3 - 13%）。
在西班牙，2010 - 2014年期间流感VE的中期估计值是疫苗最终保护效果的良好替代指标。对于所有人群而言，中期和最终估计值在进行亚型特异性分析时显示出更高的一致性。
